Presented at ACT 2023
Inotiv has expanded their Safety Pharmacology capabilities to include non-human primates. Inotiv’s Director of Safety Pharmacology, Ty Speece, presented a poster at the American College of Toxicology meeting on “Applying ICH E14/S7B: The Cardiovascular Effects of Moxifloxacin in Conscious, Telemetered Cynomolgus Monkeys.” The purpose of this study was to investigate the effects of moxifloxacin (QT reference drug) and apply updated best practice recommendations to evaluate the sensitivity and validity of the model to be an effective preclinical predictor of QT prolongation in humans.
Download your copy of the poster to learn the results of this Safety Pharmacology study including:
-
Effects of vehicle and moxifloxacin on QTcI in conscious, telemetered cynomolgus monkeys
-
Importance of concentration-QTc (cQTc) modeling
-
Using cQTc analysis to allow for the quantification of the drug concentration required to induce a QTc effect at a specified threshold
- How this is applicable to the recently released E14/S7B Questions and Answers (Q&A) document
